Victory Capital Management
UROV

Victory Capital Management’s Urovant Sciences Ltd. UROV Stock Holding History

Victory Capital Management’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,782
Closed -$16K – 3637
2020
Q1 		$16K Buy
+1,782
New +$21.4K ﹤0.01% 3195
2019
Q4 		– Sell
-1,037
Closed -$10K – 3608
2019
Q3 		$10K Buy
+1,037
New +$9K ﹤0.01% 3285
2018
Q4 		– Sell
-5,000
Closed -$60K – 1831
2018
Q3 		$60K Buy
+5,000
New +$59.1K ﹤0.01% 1711

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return

Victory Capital Management's UROV Position: Q2 2020 in Review

Victory Capital Management sold out of Urovant Sciences Ltd. (UROV) in Q2 2020, closing a stake of 1,782 shares — an estimated $16K sold.

Victory Capital Management first reported a position in UROV in Q3 2018 and held it in 3 quarters. The position peaked at $60K in Q3 2018. 25 funds tracked by Wall St. Rank hold UROV as of Q2 2020.

  • Victory Capital Management reported no remaining Urovant Sciences Ltd. position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 1,782 Urovant Sciences Ltd. shares in Q2 2020, an estimated $16K.
  • Victory Capital Management first reported a position in Urovant Sciences Ltd. in Q3 2018 and held it in 3 quarters.
  • Victory Capital Management's Urovant Sciences Ltd. position peaked at $60K in Q3 2018.
  • 25 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.